TCGA-MV-A51V-01A-11R-A26T-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 13.46911958
- os_event
- false
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- TNFA_SIGNALING_VIA_NFKB+0.420
- BILE_ACID_METABOLISM+0.330
- XENOBIOTIC_METABOLISM+0.330
- ESTROGEN_RESPONSE_LATE+0.310
- KRAS_SIGNALING_DN+0.310
- ESTROGEN_RESPONSE_EARLY+0.270
- CHOLESTEROL_HOMEOSTASIS+0.250
- SPERMATOGENESIS+0.250
- MYOGENESIS+0.190
- FATTY_ACID_METABOLISM+0.170
Top 10 suppressed
- MYC_TARGETS_V1-0.570
- INTERFERON_ALPHA_RESPONSE-0.510
- MYC_TARGETS_V2-0.510
- UNFOLDED_PROTEIN_RESPONSE-0.480
- ALLOGRAFT_REJECTION-0.450
- G2M_CHECKPOINT-0.420
- DNA_REPAIR-0.400
- INTERFERON_GAMMA_RESPONSE-0.390
- OXIDATIVE_PHOSPHORYLATION-0.380
- E2F_TARGETS-0.360
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
4 twins match this tumor's tissue · 6 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_5K3R0F5D | Ganglioglioma | — | 0.829 |
| 2 | SRR1083100 | GTEX | — | 0.827 |
| 3 | MNG188 | — | — | 0.827 |
| 4 | BS_CREQ97QC | DNET | — | 0.825 |
| 5 | C3L-03642 | — | cohortA1 | 0.823 |
| 6 | SRR1096851 | GTEX | — | 0.823 |
| 7 | SRR1409305 | GTEX | — | 0.822 |
| 8 | MNG113 | — | — | 0.820 |
| 9 | SRR1405485 | GTEX | — | 0.819 |
| 10 | R114 | — | — | 0.818 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 24 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| TNFA_SIGNALING_VIA_NFKB | 0.420 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.330 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.330 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.310 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.310 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.270 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.250 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.250 | Inavolisib | — uncovered |
| MYOGENESIS | 0.190 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.170 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.170 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.160 | Temsirolimus | — uncovered |
| PANCREAS_BETA_CELLS | 0.160 | Cobimetinib | — uncovered |
| COAGULATION | 0.140 | Binimetinib | — uncovered |
| PEROXISOME | 0.140 | Idelalisib | — uncovered |
| APOPTOSIS | 0.130 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.100 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.070 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.070 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.060 | Inavolisib | — uncovered |